[1]Engelhardt M,Terpos E,Kleber M,et al.European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma[J].Haematologica,2014,99(2):232-242.
[2]Rajkumar SV,Larson D,Kyle RA.Diagnosis of smoldering multiple myeloma[J].N Engl J Med,2011,365(5):474-475.
[3]Edwards CM,Zhuang JL,Mundy GR.The pathogenesis of the bone disease of multiple myeloma[J].Bone,2008,42(6):1007-1013.
[4]李斯丹,徐燕,王亚非,等.多发性骨髓瘤的临床特点分析[J].中华血液杂志,2010,31(4):228-232.
[5]Saad F,Lipton A,Cook R,et al.Pathologic fractures correlate with reduced survival in patients with malignant bone disease[J].Cancer,2007,110(8):1860-1867.
[6]Rosi-ol L,Cibeira MT,Bladé J,et al.Extramedullary multiple myeloma escapes the effect of thalidomide[J].Haematologica,2004,89(7):832-836.
[7]陈海飞,傅卫军,王东星,等.40例多发性骨髓瘤伴随外病变患者的临床特征分析[J].中华血液杂志,2007,28(10):655-658.
[8]李新,孙万军,陈世伦,等.伴随外浸润的多发性骨髓瘤临床分析[J].中华医学杂志,2012,92(12):838-841.
[9]Sarahrudi K,Wolf H,Funovics P,et al.Surgical treatment of pathological fractures of the shaft of the humerus[J].J Trauma,2009,66(3):789-794.
[10]Scotti C,Camnasio F,Peretti GM,et al.Modular prostheses in the treatment of proximal humerus metastases:review of 40 cases[J].J Orthop Traumatol,2008,9(1):5-10.
[11]Anderson KC,Alsina M,Bensinger W,et al.NCCN clinical practice guidelines in oncology:multiple myeloma[J].J Natl Compr Canc Netw,2009,7(9):908-942.
[12]Bartel TB,Haessler J,Brown TL,et al.F18-fluorodeoxy glucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma[J].Blood,2009,114(10):2068-2076.
[13]Schmidt GP,Reiser MF,Bau-Melnyk A.Whole-body imaging of the musculoskeletal system:the value of MR imaging[J].Skeletal Radiol,2007,36(12):1109-1119.
[14]Pianko MJ,Terpos E,Roodman GD,et al.Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease[J].Clin Cancer Res,2014,20(23):5888-5897.
[15]Ferraro R,Agarwal A,Martin-Macintosh ER,et al.MR imaging and PETCT in diagnosis and management of multiple myeloma[J].Radiographics,2015,35(2):438-454.
[16]张骏,邓宏宇,巫刚,等.多发性骨髓瘤148例临床分析[J].临床荟萃,2005,20(8):452-454.
[17]刘蕴华.多发性骨髓瘤误诊24例分析[J].中国误诊学杂志,2006,6(23):4591-4592.
[18]唐尚权,刘风琼,余涛,等.以骨折为首发表现的骨髓瘤门诊漏诊16例分析[J].中国误诊学杂志,2008,8(1):117-118.
[19]汪江,颜维仁.多发性骨髓瘤误诊原因分析[J].临床误诊误治,2010,23(8):753-753.
[20]王志芳,史福敏,孟祥玲,等.乳腺原位癌并发多发性骨髓瘤1例[J].现代肿瘤医学,2013,21(4):866-867.
[21]杜心如,胡永成,肖建如,等.中国多发性骨髓瘤工作组外科专家委员会成立及学术会议的会议纪要[J].中国骨与关节杂志,2015,4(7):590-591.
[22]Anderson KC,Alsina M,Atanackovic D,et al.NCCN guidelines insights:multiple myeloma,version 3.2016[J].J Natl Compr Canc Netw,2016,14(4):389-400.
[23]Zeifang F,Zahlten-Hinguranage A,Goldschmidt H,et al.Long-term survival after surgical intervention for bone disease in multiple myeloma[J].Ann Oncol,2005,16(2):222-227.
[24]Utzschneider S,Schmidt H,Weber P,et al.Surgical therapy of skeletal complications in multiple myeloma[J].Int Orthop,2011,35(8):1209-1213.
[25]de Mel S,Chen Y,Gopalakrishnan SK,et al.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma[J].Singapore Med J,2017,58(2):55-71.
[26]Alvi HM,Damron TA.Prophylactic stabilization for bone metastases,myeloma,or lymphoma:Do we need to protect the entire bone[J].Clin Orthop Relat Res,2013,471(3):706-714.
[27]张学伟,杜心如,陈文明.多发性骨髓瘤患者的手术治疗与预后分析[J].中国骨与关节杂志,2014,3(7):501-506.
[28]刘红艳,肖运祥,郭静明,等.多发性骨髓瘤合并股骨颈骨折的治疗[J].中国医师进修杂志,2011,34(35):21-23.
[29]杨毅,杨荣利,郭卫.59例肱骨转移癌手术治疗的回顾性分析[N].北京大学学报,2011,12-13(5).
[30]陈杰,陶惠民,童培建,等.多发性骨髓瘤的外科治疗[J].实用肿瘤杂志,2007,22(1):40-43.
[31]Janssen SJ,Kortlever JT,Ready JE,et al.Complications after surgical management of proximal femoral metastasis:a retrospective study of 417 patients[J].J Am Acad Orthop Surg,2016,24(7):483-494.
[32]Janssen SJ,van der Heijden AS,van Dijke M,et al.Prognostication in patients with long bone metastases:Does a boosting algorithm improve survival estimates[J].Clin Orthop Relat Res,2015,473(10):3112-3121.
[33]R-llig C,Knop S,Bornh-user M.Multiple myeloma[J].Lancet,2015,385(9983):2197-2208.
[34]Bickels J,Dadia S,Lidar Z.Surgical management of metastatic bone disease[J].J Bone Joint Surg(Am),2009,91(6):1503-1516.
[35]张继青,钟雷,葛宁,等.综合治疗在髓外浆细胞瘤中的应用[N].广州医科大学学报,2015-2-2(4).
[36]Rasche L,Bernard C,Topp MS,et al.Features of extramedullary myeloma relapse:high proliferation,minimal marrow involvement,adverse cytogenetics:a retrospective single-center study of 24 cases[J].Ann Hematol,2012,91(7):1031-1037.
[37]De Larrea CF,Rosi-ol L,Cibeira MT,et al.Extensive soft-tissue involvement by plasmablastic myelorna arising from displaced humeral fractures[J].Eur J Haematol,2010,85(5):448-451.
[38]Swami A,Reagan MR,Basto P,et al.Engineered nanomedicine for myeloma and bone microenvironment targeting[J].Proc Natl Acad Sci,2014,111(28):10287-10292.
[39]McCarthy PL,Hahn T.Strategies for induction,autologous hematopoietic stem cell transplantation,consolidation,and maintenance for transplantation-eligible multiple myeloma patients[J].Hematology Am Soc Hematol Educ Program,2013(1):496-503.
[40]Surgeon's Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation.Consensus on surgical management of myeloma bone disease[J].Orthop Surg,2016,8(3):263-269.